{"id":"NCT01644331","sponsor":"Duke University","briefTitle":"Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure","officialTitle":"The Targeting Acute Congestion With Tolvaptan In Congestive Heart Failure Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10","primaryCompletion":"2016-02","completion":"2016-02","firstPosted":"2012-07-19","resultsPosted":"2017-04-27","lastUpdate":"2017-04-27"},"enrollment":257,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Heart Failure","Dyspnea"],"interventions":[{"type":"DRUG","name":"Tolvaptan","otherNames":["Samsca"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tolvaptan","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to compare the effects of oral Tolvaptan vs. placebo as an adjunct to fixed dose IV furosemide on dyspnea relief in patients with acute decompensated heart failure\n\nThe primary hypothesis is that the addition of oral Tolvaptan to fixed dose furosemide will be more effective at relieving dyspnea than fixed dose furosemide alone","primaryOutcome":{"measure":"Dyspnea Improvement Measured by Likert Scale at 8 and 24 Hours","timeFrame":"8 and 24 hours","effectByArm":[{"arm":"Tolvaptan","deltaMin":20,"sd":null},{"arm":"Placebo","deltaMin":26,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.315"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":19},"locations":{"siteCount":18,"countries":["United States"]},"refs":{"pmids":["27654854"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":129},"commonTop":["Worsening Heart Failure","Acute Renal Failure","Atrial Fibrillation","Death","Ventricular Tachycardia"]}}